Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Short-term Investments (2020 - 2025)

Ovid Therapeutics' Short-term Investments history spans 5 years, with the latest figure at $56.5 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 110.96% year-over-year to $56.5 million; the TTM value through Dec 2025 reached $56.5 million, up 110.96%, while the annual FY2025 figure was $56.5 million, 110.96% up from the prior year.
  • Short-term Investments reached $56.5 million in Q4 2025 per OVID's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $84.1 million in Q4 2022 to a low of $5.0 million in Q3 2025.
  • Average Short-term Investments over 4 years is $47.1 million, with a median of $47.7 million recorded in 2024.
  • The largest YoY upside for Short-term Investments was 110.96% in 2025 against a maximum downside of 89.53% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $84.1 million in 2022, then fell by 6.35% to $78.8 million in 2023, then plummeted by 66.02% to $26.8 million in 2024, then surged by 110.96% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Short-term Investments are $56.5 million (Q4 2025), $5.0 million (Q3 2025), and $9.9 million (Q2 2025).